ArticleHepatology international2026
Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.
Min Ji Lee et al.PubMed ↗Publisher ↗
No numbers read from the abstract.